Abstract
Background The COVID-19 pandemic is an ongoing global crisis, with a multitude of factors that affect mental health worldwide. Here, we explore potential predictors for the emergence and maintenance of depression, anxiety, and posttraumatic stress symptoms (PTSS) in the general population in Israel.
Methods Across the span of 16 months, 2,478 people completed a repeated self-report survey which inquired psychiatric symptoms and pandemic related stress factors (PRSF). PRSF were divided into four clusters of environmental stressors: financial, health-related, fatigue and sense of protection by authorities. We applied mixed-effects linear models to assess how each stressor contributes to depression, anxiety and PTSS at each time point, alongside a longitudinal exploration among participants who completed at least two consecutive surveys (n=400).
Results Fatigue was the strongest predictor for depression, anxiety and PTSS at all time points (standardized β between 0.28-0.60, p<.0001), and predicted deterioration overtime (β between 0.22-0.36, p<.0001). Financial concerns associated with depression and anxiety at all time points (β between 0.13- 0.26, p<.01), and with their deterioration overtime (β between 0.16-0.18, p<.0001), while health related concerns were uniquely associated with anxiety and PTSS at all time points (β between 0.14-0.29, p<.01) and their deterioration (β between 0.11-0.16, p<.001), but not with depression. Improvement in sense of protection overtime associated with decrease in depression and anxiety (β between −0.09 to −0.16, p<.01).
Conclusions Our findings accentuate the multitude of risk factors for psychiatric morbidity during COVID-19, and the dynamics in their association with different aspects of psychopathology at various time points.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from Foundation Dora and by the Binational Science Foundation (Grant No. 2017369). The funding source had no role in the study design, collection, analysis, or interpretation of data, the writing of the article, or decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of Sheba Medical Center, Tel Hashomer, Israel (IRS#SMC-7182-20)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon request.
